|
Session 47-Themed Discussion
TD: Impact of Treatment Intensification on HIV Reservoirs and Immune Activation
Friday, 1-2 pm; Room 2005 |
279
 |
Effect of Raltegravir-containing Intensification on HIV Burden and T Cell Activation in the Gut of HIV+ Adults on Suppressive ART
Steven Yukl1, A Shergill1, S Gianella2, A Choi1, V Girling3, M Downing3, H Lampiris1, H Guenthard2, J Wong1, D Havlir3, and the PLUS Study Group
1San Francisco VAMC and Univ of California, San Francisco, US; 2Univ Hosp Zurich, Switzerland; and 3San Francisco Gen Hosp and Univ of California, San Francisco, US |
| 280 |
Raltegravir Intensification Does Not Reduce Persistent HIV-1 Viremia in Treatment-experienced Patients
Ann Wiegand1, F Cossarini1, C Poethke1, M Kearney1, J Spindler2, A O’Shea2, C Rehm2, J Coffin1, J Mellors3, and F Maldarelli1
1NCI-Frederick, MD, US; 2NIAID, NIH, Bethesda, MD, US; and 3Univ of Pittsburgh, PA, US |
281
|
No Evolution of HIV-1 Total DNA and 2-LTR Circles after 48 Weeks of Raltegravir-containing Therapy in Patients with Controlled Viremia: A Sub-study of the Randomized EASIER-ANRS 138 Trial
Constance de Laugerre1, I Charreau2, J Braun2, M-L Néré1, N de Castro1, P Yeni3, J Ghosn4, F Simon1, J-P Aboulker2, and J-M Molina1
1Univ Paris 7 Diderot, Saint-Louis Hosp, AP-HP, France; 2INSERM SC10, Villejuif, France; 3Univ Paris 7 Diderot, Bichat-Claude Bernard Hosp, AP-HP, France; and 4Hosp Kremlin-Bicetre, AP-HP, France |
282
|
Intensification of HAART through the Addition of Enfuvirtide in Naive HIV-infected Patients with Severe Immunosuppression Does Not Improve Immunological Response: Results of a Prospective Randomized Multicenter Trial (APOLLO - ANRS 130)
Véronique Joly1, C Fagard2, D Descamps1, N Colin de Verdière3, F Raffi4, S Tabuteau2, A Cabié5, M Bentata6, P Yeni1, and G Chêne2
1Hosp Bichat Claude Bernard, Paris, France; 2INSERM U897, Bordeaux, France; 3Hosp Saint Louis, Paris, France; 4Hosp Hotel Dieu, Nantes, France; 5Hosp Pierre Zobda-Quitman, Fort de France; and 6Hosp Avicenne, Bobigny, France |
283
|
Antiviral and Immunological Effects of Intensification of Suppressive ART with Maraviroc, a CCR5 Antagonist
Teresa Evering1, S Mehandru1, M Poles2, P Racz3, K Tenner-Racz3, H Mohri1, N Prada1, D Garmon1, T Parker4, and M Markowitz1
1Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York, NY, US; 2New York Univ Sch of Med, NY, US; 3Bernhard Nocht Inst for Tropical Med, Hamburg, Germany; and 4The Rogosin Inst, New York, NY, US |
284
|
Effect of the Intensification with a CCR5 Antagonist on the Decay of the HIV-1 Latent Reservoir and Residual Viremia
Carolina Gutiérrez1, L Diaz2, B Hernández-Novoa1, A Vallejo1, C Page1, R Lorente2, N Madrid1, S Palmer3, M Á Muñoz-Fernández2, and S Moreno1
1Hosp Univ Ramón y Cajal, Madrid, Spain; 2Hosp General Univ Gregario Marañón, Madrid, Spain; and 3Swedish Inst of Infectious Diseases Control and Karolinska Inst, Stockholm |
285
|
Maraviroc Intensification for Suboptimal CD4+ Cell Response Despite Sustained Virologic Suppression: ACTG 5256
Timothy Wilkin1, C Lalama2, A Tenorio3, A Landay3, H Ribaudo2, J McKinnon4, R Gandhi5, J Mellors4, J Currier6, and R Gulick1
1Weill Cornell Med Coll, New York, NY, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Rush Univ Med Ctr, Chicago, IL, US; 4Univ of Pittsburgh Sch of Med, PA, US; 5Massachusetts Gen Hosp, Boston, US; and 6Univ of California, Los Angeles, US |
|
